10-QPeriod: Q2 FY2021

AGILENT TECHNOLOGIES, INC. Quarterly Report for Q2 Ended Apr 30, 2021

Filed June 1, 2021For Securities:A

Summary

Agilent Technologies, Inc. reported strong financial results for the second quarter and the first half of fiscal year 2021, demonstrating significant year-over-year revenue growth across all segments and geographies. This growth was primarily driven by demand in pharmaceutical, biopharmaceutical, food, and academic markets, with contributions from both product and service revenues. The company also executed strategic financial maneuvers, including the issuance of $850 million in senior notes and the redemption of its 2022 senior notes. Furthermore, Agilent completed a strategic acquisition of Resolution Bioscience, Inc., enhancing its capabilities in precision oncology solutions. Despite ongoing global economic uncertainties, Agilent maintained a robust balance sheet and cash flow from operations, underscoring its financial resilience and commitment to shareholder returns through dividends and share repurchases.

Financial Highlights

55 data points
Beta

Revenue

$1.52B

53.6% Gross Margin

Net Income

$216.00M

14.2% Net Margin

EPS (Diluted)

$0.70

Total Assets

$10.40B

Cash & Equivalents

$1.39B

Free Cash Flow

$441.00M

Financial Statements
Beta
Revenue$1.52B
Cost of Revenue$708.00M
Gross Profit$817.00M
R&D Expenses$109.00M
SG&A Expenses$420.00M
Operating Expenses$1.24B
Operating Income$288.00M
Interest Expense$20.00M
Net Income$216.00M
EPS (Basic)$0.71
EPS (Diluted)$0.70
Shares Outstanding (Basic)304.00M
Shares Outstanding (Diluted)307.00M

Key Highlights

  • 1Total net revenue increased by 23% for the three months ended April 30, 2021, and 18% for the six months ended April 30, 2021, compared to the same periods last year.
  • 2Net income rose significantly to $216 million for the three months and $504 million for the six months ended April 30, 2021, compared to $101 million and $298 million, respectively, in the prior year.
  • 3The company successfully issued $850 million in 2.30% senior notes due 2031 on March 12, 2021.
  • 4Agilent completed the acquisition of Resolution Bioscience, Inc. for $550 million in cash plus potential future contingent payments, strengthening its position in precision oncology diagnostics.
  • 5Operating margin improved substantially, increasing by 11 percentage points for the three months and 8 percentage points for the six months ended April 30, 2021.
  • 6Net cash provided by operating activities increased significantly to $710 million for the six months ended April 30, 2021, up from $254 million in the prior year period.
  • 7The company continued its share repurchase program, authorizing up to $2.0 billion under the 2021 repurchase program as of April 30, 2021.

Frequently Asked Questions

Agilent Technologies demonstrated strong financial performance, reporting significant year-over-year increases in net revenue and net income for both the three and six months ended April 30, 2021. Revenue growth was broad-based across its business segments and geographies, indicating a healthy demand for its products and services.

The acquisition of Resolution Bioscience, Inc. for $550 million (plus contingent payments) is a strategic move to enhance Agilent's capabilities in next-generation sequencing-based precision oncology solutions. This acquisition is expected to further serve the fast-growing precision medicine market and complements Agilent's existing diagnostics and genomics business.

Agilent maintains a strong liquidity position with $1.38 billion in cash and cash equivalents as of April 30, 2021. Net cash provided by operating activities saw a substantial increase to $710 million for the first six months of fiscal year 2021. The company believes its current resources are sufficient to meet its liquidity requirements for at least the next twelve months.

Agilent has actively managed its debt by issuing $850 million in senior notes due 2031 and fully redeeming its 2022 senior notes. The company also has a significant revolving credit facility and a commercial paper program, demonstrating a well-managed capital structure and access to funding.